Zydus Lifesciences inches up on getting final approval to market Topiramate Extended-Release Capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 410.85, up by 1.40 points or 0.34% from its previous closing of Rs. 409.45 on the BSE.
The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 414.80 and Rs. 410.85 respectively. So far 3267 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 414.80 and Rs. 392.05 respectively. The current market cap of the company is Rs. 41444.70 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy XR Extended-Release capsules).
Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy. It may also be used to prevent migraine headaches. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Topiramate Extended-Release capsule had annual sales of $68.8 million in the United States according to IQVIA data (IQVIA MAT September 2022). The group now has 335 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04 (as of September 30, 2022).
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
